Risperidone

Generic Name: Risperidone

Brand Names: Perseris, Risperdal, Rykindo, Uzedy, Okedi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 106266-06-2

Unique Ingredient Identifier: L6UH7ZF8HC

Background: Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication: Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions: Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state

Associated Therapies: -

Clinical Trials

An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)

Phase 2

Completed

Conditions: Schizophrenia, Acute Episode

Interventions: Drug: MK-8189
Drug: Risperidone
Drug: Placebo matching risperidone
Drug: Placebo matching MK-8189

First Posted Date: 2017-02-16

Last Posted Date: 2024-08-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 224

Registration Number: NCT03055338

Locations: 🇺🇸
CNRI - Los Angeles, LLC ( Site 0026), Pico Rivera, California, United States
🇺🇸
Artemis Institute for Clinical Research ( Site 0027), San Diego, California, United States
🇺🇸
Radiant Research - Atlanta ( Site 0008), Atlanta, Georgia, United States

and more 25 locations

Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium Carbonate
Drug: Sertraline
Drug: Nortriptyline
Drug: Risperidone

First Posted Date: 2016-09-28

Last Posted Date: 2020-11-20

Lead Sponsor: Federal University of Rio Grande do Sul

Target Recruit Count: 78

Registration Number: NCT02918097

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Single Ascending Dose Study of RBP-7000

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: RBP-7000
Drug: risperidone

First Posted Date: 2016-05-11

Last Posted Date: 2016-05-11

Lead Sponsor: Indivior Inc.

Target Recruit Count: 45

Registration Number: NCT02768649

Locations: 🇺🇸
CRI Worldwide, Willingboro, New Jersey, United States

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

Phase 3

Withdrawn

Conditions: Schizophrenia

Interventions: Drug: brexpiprazole
Drug: risperidone

First Posted Date: 2016-05-02

Last Posted Date: 2016-08-01

Lead Sponsor: H. Lundbeck A/S

Registration Number: NCT02758067

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Lu AF35700
Drug: Risperidone
Drug: Olanzapine

First Posted Date: 2016-03-23

Last Posted Date: 2019-11-25

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 1098

Registration Number: NCT02717195

Locations: 🇧🇬
BG1029, Veliko Tŭrnovo, Bulgaria
🇲🇽
MX1011, Guadalajara, Mexico
🇲🇽
MX1022, Guadalajara, Mexico

and more 144 locations

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

Not Applicable

Withdrawn

Conditions: Schizophrenia
Psychosis Not Otherwise Specified (NOS)
Schizophreniform
Schizoaffective Disorder

Interventions: Drug: Risperidone
Device: tDCS

First Posted Date: 2016-01-22

Last Posted Date: 2018-03-13

Lead Sponsor: Northwell Health

Registration Number: NCT02661347

Locations: 🇺🇸
Zucker-Hillside Hospital, Glen Oaks, New York, United States

The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment

Phase 1

Conditions: Schizophrenia

Interventions: Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine
Drug: Aripiprazole
Drug: Ziprasidone

First Posted Date: 2016-01-08

Last Posted Date: 2016-01-08

Lead Sponsor: Shanxi Medical University

Target Recruit Count: 200

Registration Number: NCT02650102

Locations: 🇨🇳
First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi, China

Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

Phase 1

Completed

Conditions: Antipsychotic
Immunoassay

Interventions: Drug: Aripiprazole
Other: Olanzapine
Drug: Paliperidone
Drug: Risperidone

First Posted Date: 2015-12-18

Last Posted Date: 2018-04-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 81

Registration Number: NCT02634463

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

First Posted Date: 2015-11-09

Last Posted Date: 2019-01-23

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 296

Registration Number: NCT02600741

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy